Boston Scientific (BSX) Getting Somewhat Favorable News Coverage, Accern Reports

News coverage about Boston Scientific (NYSE:BSX) has trended somewhat positive recently, according to Accern. The research firm rates the sentiment of media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Boston Scientific earned a news impact score of 0.19 on Accern’s scale. Accern also gave news headlines about the medical equipment provider an impact score of 45.3902913791405 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Here are some of the news stories that may have effected Accern Sentiment Analysis’s analysis:

Shares of Boston Scientific (BSX) opened at $28.03 on Wednesday. Boston Scientific has a 52 week low of $23.29 and a 52 week high of $29.93. The stock has a market capitalization of $38,902.64, a PE ratio of 23.22, a P/E/G ratio of 2.03 and a beta of 0.96. The company has a quick ratio of 0.50, a current ratio of 0.72 and a debt-to-equity ratio of 0.58.

A number of research analysts recently issued reports on the stock. Barclays reiterated a “buy” rating and issued a $32.00 price objective on shares of Boston Scientific in a report on Wednesday, January 10th. BMO Capital Markets restated a “buy” rating and set a $31.00 price target on shares of Boston Scientific in a report on Wednesday, November 29th. Needham & Company LLC upgraded shares of Boston Scientific from a “buy” rating to a “strong-buy” rating and raised their price target for the stock from $25.04 to $32.00 in a report on Friday, December 8th. Zacks Investment Research lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a research note on Monday, October 30th. Finally, Oppenheimer reiterated a “hold” rating on shares of Boston Scientific in a research note on Wednesday, November 29th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $31.00.

In other news, SVP David A. Pierce sold 8,763 shares of the business’s stock in a transaction dated Thursday, January 11th. The stock was sold at an average price of $27.74, for a total transaction of $243,085.62. Following the completion of the transaction, the senior vice president now owns 24,201 shares of the company’s stock, valued at $671,335.74. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP David A. Pierce sold 5,152 shares of the business’s stock in a transaction dated Tuesday, January 9th. The stock was sold at an average price of $27.00, for a total value of $139,104.00. Following the transaction, the senior vice president now directly owns 38,116 shares of the company’s stock, valued at approximately $1,029,132. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 71,085 shares of company stock worth $1,855,487. Company insiders own 0.74% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright law. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/01/31/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-boston-scientific-bsx-stock-price.html.

Boston Scientific Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Insider Buying and Selling by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply